Raltegravir Tablets Articles
US ANDAs filed for generic Beyaz, Isentress and Epivir
12 January 2012
Merck slammed over drug pricing
12 December 2011
Gilead’s Quad regimen to be HIV market leader in 2020, with over $3 billion sales, says Decision Resources
31 October 2011
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
AHF takes campaign to Merck & Co’s home town with AIDS banners protesting high cost of Isentress
17 February 2010
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
Blockbuster status predicted for co-formulation of rilpivirine and Truvada with sales of over $2 billion in the HIV Drug Market by 2018
7 January 2010
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
EU approves expanded use of Merck & Co’s Isentress in adult patients with HIV-1 Infection
16 September 2009
Merck & Co's drug cuts HIV across sub-groups
16 February 2009
FDA accept Merck & Co's sNDA for Isentress
22 December 2008
Isentress cuts viral load in untreated patients
3 November 2008
Anadis gets go ahead for Ph IV BioGard trial
27 October 2008
US and UK Prix Galien awards 2008, winners announced
6 October 2008
Isentress works well in untreated HIV patients
18 August 2008
Stock Commentary - New York week to July 28, 2008
4 August 2008
Isentress: significant HIV load suppression up to 48 weeks
18 February 2008
Vioxx costs see Merck & Co swing to $1.6B loss
4 February 2008
Merck & Co's Isentress launched in UK
28 January 2008
EC OKs Isentress for treatment-experienced HIV-1 patients
7 January 2008
Merck & Co's Isentress gets nod from CHMP
26 November 2007
AHF attacks another US firm for HIV drug price
22 October 2007
Impact of FDA OK for Merck & Co's Isentress
22 October 2007
Isentress plus OBT sustains HIV suppression
1 October 2007
Isentress gets ADAC's unanimous backing
17 September 2007
Combined Isentress and Fuzeon cuts HIV levels in study
12 March 2007
Showing 1-39 of 39 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
